Cancer immunotherapies: advances and bottlenecks.
Cancer immunotherapies: advances and bottlenecks.
复制标题
DOI：
10.3389/fimmu.2023.1212476
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
免疫治疗开创了癌症治疗的新时代，癌症免疫治疗不断焕发活力。肿瘤免疫治疗的临床目标是启动宿主免疫系统，提供被动或主动免疫来对抗恶性肿瘤。肿瘤浸润白细胞（Tumor浸润leukocytes， til）在肿瘤微环境（Tumor microenvironment， TME）中发挥免疫调节作用，而TME与肿瘤细胞的免疫逃逸密切相关，从而影响肿瘤的进展。几种癌症免疫疗法，包括免疫检查点抑制剂（ICIs）、癌症疫苗、过继细胞转移（ACT），已经显示出巨大的疗效和前景。本文综述了近年来肿瘤免疫治疗的研究进展，包括肿瘤免疫治疗的分子机制、临床疗效以及免疫治疗的局限性。
Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors. Tumor infiltrating leukocytes (TILs) play an immunomodulatory role in tumor microenvironment (TME) which is closely related to immune escape of tumor cells, thus influence tumor progress. Several cancer immunotherapies, include immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), have shown great efficacy and promise. In this review, we will summarize the recent research advances in tumor immunotherapy, including the molecular mechanisms and clinical effects as well as limitations of immunotherapy.